Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

BMJ Open - United Kingdom
doi 10.1136/bmjopen-2014-006733
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy